AQR Arbitrage’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

AQR Arbitrage’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,208	Closed	-$2.02M	–	1215
2022 Q4	$2.02M	Hold	200,208	–	–	0.05%	408
2022 Q3	$1.99M	Hold	200,208	–	–	0.04%	491
2022 Q2	$1.96M	Buy	200,208 +100,000	+100%	+$979K	0.04%	459
2022 Q1	$976K	Hold	100,208	–	–	0.03%	496
2021 Q4	$971K	Hold	100,208	–	–	0.02%	661
2021 Q3	$969K	Buy	100,208 +56,210	+128%	+$544K	0.03%	466
2021 Q2	$425K	Buy	+43,998	New	+$432K	0.01%	652

AQR Arbitrage's EBAC Position: Q1 2023 in Review

AQR Arbitrage sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 200,208 shares — an estimated $2.02M sold.

AQR Arbitrage first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $2.02M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

AQR Arbitrage reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
AQR Arbitrage sold 200,208 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $2.02M.
AQR Arbitrage first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
AQR Arbitrage's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $2.02M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on AQR Arbitrage's 13F filing for Q1 2023, filed 15 May 2023.